# Norovirus Bivalent-Vaccine Efficacy Study

> **NCT01609257** · PHASE1,PHASE2 · COMPLETED · sponsor: **Takeda** · enrollment: 132 (actual)

## Conditions studied

- Prevention From Norovirus Infection

## Interventions

- **BIOLOGICAL:** Norovirus Bivalent Vaccine
- **BIOLOGICAL:** Saline Comparator

## Key facts

- **NCT ID:** NCT01609257
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-16
- **Primary completion:** 2014-03-01
- **Final completion:** 2014-03-18
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2019-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609257, "Norovirus Bivalent-Vaccine Efficacy Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01609257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*